HOUSTON, Nov. 17, 2016 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that two presentations updating safety and efficacy of its lead product, DNX-2401, will be made at the 21 st Annual Meeting of the Society for Neuro-Oncology, November 17-20, in Scottsdale, Arizona. Clinical results demonstrate that DNX-2401 provides clinical benefit as a single agent and in combination with other therapies, including temozolomide and interferon gamma. "We are honored to have our work chosen for presentation," said Frank Tufaro, PhD, CEO of DNAtrix. "Interim results from two clinical trials have shown strong clinical benefit and improved survival in recurrent glioblastoma, thus supporting further development of DNX-2401 for both recurrent and newly-diagnosed disease." Details of the presentations are as follows: A Phase I Study of the Oncolytic Virus DNX-2401 and a Short Course Temozolomide for Glioblastoma at First Recurrence Abstract Number: ACTR-15Presenter: Sonia Tejada, MD, PhDDate: Friday, November 18, 2016Phase 1b Open-Label Randomized Study of the Oncolytic Virus DNX-2401 Administered with or without Interferon Gamma for Recurrent Glioblastoma Abstract Number: ATIM-30Presenter: Frank Tufaro, PhDDate: Friday, November 18, 2016 For more information about DNAtrix clinical studies, visit the website ClinicalTrials.gov: NCT01956734 (DNX-2401 + temozolomide), NCT02197169 (DNX-2401 ± interferon gamma), and NCT02798406 (DNX-2401 + KEYTRUDA). About DNX-2401 DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer, with glioblastoma as the initial indication. Glioblastoma is the most aggressive form of brain cancer, which has a median survival of 15 months following a patient's initial diagnosis. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process can also trigger an anti-tumor immune response. DNX-2401 is currently being investigated in several clinical studies and has been well tolerated in all settings. Compelling results from clinical studies in recurrent glioblastoma indicate that DNX-2401 can (1) replicate in human brain tumors for a period of weeks to months, (2) trigger immune cell infiltration into the tumor, (3) cause ongoing tumor destruction and (4) induce durable responses to therapy. In these studies, patient survival has been prolonged, including in those achieving a complete response.